Market Cap | 18.77M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -17.57M | Forward P/E | -3.24 | EPS next Y | - | 50D Avg Chg | 22.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 11.00% |
Dividend | N/A | Price/Book | 0.51 | EPS next 5Y | - | 52W High Chg | -65.00% |
Recommedations | 3.00 | Quick Ratio | 18.65 | Shares Outstanding | 5.85M | 52W Low Chg | 163.00% |
Insider Own | 25.06% | ROA | -31.69% | Shares Float | 4.41M | Beta | 0.18 |
Inst Own | 0.16% | ROE | -54.06% | Shares Shorted/Prior | 55.96K/73.98K | Price | 3.21 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 115,608 | Target Price | - |
Oper. Margin | - | Earnings Date | Oct 28 | Volume | 89,577 | Change | -6.14% |
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.
HC Wainwright & Co. | Neutral | Jun 7, 23 |
HC Wainwright & Co. | Buy | May 15, 23 |
HC Wainwright & Co. | Buy | Apr 5, 23 |
HC Wainwright & Co. | Buy | Aug 9, 21 |
Dawson James | Neutral | Mar 17, 21 |
HC Wainwright & Co. | Buy | Mar 16, 21 |
HC Wainwright & Co. | Buy | Nov 19, 20 |
HC Wainwright & Co. | Buy | Apr 24, 20 |
Dougherty & Co. | Buy | Feb 5, 19 |